Search

Your search keyword '"de Jong, Florus C."' showing total 22 results
Start Over Author "de Jong, Florus C."
22 results on '"de Jong, Florus C."'

4. Non–muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin

Author

de Jong, Florus C., primary, Laajala, Teemu D., additional, Hoedemaeker, Robert F., additional, Jordan, Kimberley R., additional, van der Made, Angelique C. J., additional, Boevé, Egbert R., additional, van der Schoot, Deric K. E., additional, Nieuwkamer, Bart, additional, Janssen, Emiel A. M., additional, Mahmoudi, Tokameh, additional, Boormans, Joost L., additional, Theodorescu, Dan, additional, Costello, James C., additional, and Zuiverloon, Tahlita C. M., additional

Published
2023
Full Text
View/download PDF

5. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers

Author

Zuiverloon, Tahlita C.M., de Jong, Florus C., and Theodorescu, Dan

Subjects
Bladder cancer -- Genetic aspects -- Development and progression -- Care and treatment, Tumor markers -- Health aspects, Sentinel surveillance -- Methods, Intelligence gathering, Recurrence (Disease), Cystoscopy, Cancer diagnosis, BCG, Cancer recurrence, Health
Abstract

Cystoscopy and urine cytology are the gold-standard tests for detection of recurrent disease during follow-up in patients with a history of non-muscle-invasive bladder cancer (NMIBC). High associated costs, as well as side effects, have driven the desire for inexpensive, noninvasive, accurate, and easy-to-use urine markers to detect bladder cancer recurrence. While many urine markers have been developed, very few have been clinically implemented. In this article, we discuss the requirements for development and validation of urine markers and the factors that hamper their clinical implementation. We also review current surveillance guidelines for NMIBC and provide an overview of approved urine markers for the detection and surveillance of NMIBC., Introduction At first diagnosis, approximately 75% of bladder cancer patients present with non-muscle-invasive bladder cancer (NMIBC), with 70% having Ta disease, 20% having T1, and 10% having Tis. [1] All [...]

Published
2017

8. MP59-05 FREQUENCY OF FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS AND ASSOCIATION WITH BACILLUS CALMETTE-GUERIN OUTCOMES IN A REAL-WORLD GENOMIC ANALYSIS OF HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (GARNER) STUDY

Author

Zuiverloon, Tahlita C.M, primary, de Jong, Florus C., additional, Carcione, Jenna Cody, additional, Sundaram, Ramesh, additional, Shibata, Yoichiro, additional, Triantos, Spyros, additional, Santiago-Walker, Ademi, additional, and Baig, Mahadi, additional

Published
2022
Full Text
View/download PDF

9. MP06-01 NON-MUSCLE INVASIVE BLADDER CANCER SUBTYPES WITH DIFFERENTIAL RESPONSE TO INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT

Author

de Jong, Florus C., primary, Laajala, Teemu D., additional, Hoedemaeker, Robert F., additional, Rinaldetti, Sébastien, additional, Jordan, Kimberley R., additional, van der Made, Angelique C.J., additional, Nieuwkamer, Bart, additional, van der Schoot, Deric K.E., additional, Boevé, Egbert R., additional, Janssen, Emiel A.M., additional, Mahmoudi, Tokameh, additional, Boormans, Joost L., additional, Theodorescu, Dan, additional, Costello, James C., additional, and Zuiverloon, Tahlita C.M., additional

Published
2022
Full Text
View/download PDF

10. MP06-18 A GENOMIC URINE ASSAY TO DETECT URINARY TRACT RECURRENCES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADIOTHERAPY

Author

de Jong, Florus C., primary, Iflé, Iris I., additional, Kooper, Denise, additional, van der Made, Angelique C.J., additional, De Jong, Joep J., additional, Zuiverloon, Tahlita C.M., additional, Incrocci, Luca, additional, Van Criekinge, Wim, additional, Franckena, Martine, additional, Boormans, Joost L., additional, and Zwarthoff, Ellen C., additional

Published
2022
Full Text
View/download PDF

12. Non-muscle Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guérin

Author

de Jong, Florus C., primary, Laajala, Teemu D., additional, Hoedemaeker, Robert F., additional, Jordan, Kimberley R., additional, van der Made, Angelique C.J., additional, Boevé, Egbert R., additional, van der Schoot, Deric K.E., additional, Nieuwkamer, Bart, additional, Janssen, Emiel A.M., additional, Mahmoudi, Tokameh, additional, Boormans, Joost L., additional, Theodorescu, Dan, additional, Costello, James C., additional, and Zuiverloon, Tahlita C.M., additional

Published
2021
Full Text
View/download PDF

13. MP66-01 RNA-SEQUENCING OF BCG TREATED BLADDER CANCER PATIENTS IDENTIFIES PATIENTS WITH AGGRESSIVE AND IMMUNE SUPPRESSIVE TUMORS AT RISK OF BCG FAILURE

Author

de Jong, Florus C, primary, Laajala, Teemu D, additional, Hoedemaeker, Robert F, additional, Mensink, Jolien TM, additional, Rinaldetti, Sébastien, additional, de Jong, Joep J, additional, Van Der Made, Angelique CJ, additional, van der Schoot, Deric KE, additional, Boevé, Egbert R, additional, Zwarthoff, Ellen C, additional, Boormans, Joost L, additional, Theodorescu, Dan, additional, Costello, James C, additional, and Zuiverloon, Tahlita CM, additional

Published
2021
Full Text
View/download PDF

14. Abstract 614: Transcriptomic analysis of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG-failure

Author

De Jong, Florus C., primary, Laajala, Teemu D., additional, Hoedemaeker, Robert F., additional, Rinaldetti, Sébastien, additional, Mensink, Jolien T., additional, Van der Made, Angelique C., additional, Van der Schoot, Deric K., additional, Boevé, Egbert R., additional, Zwarthoff, Ellen C., additional, Boormans, Joost L., additional, Theodorescu, Dan, additional, Costello, James C., additional, and Zuiverloon, Tahlita C., additional

Published
2021
Full Text
View/download PDF

15. Abstract 615: Differential pathway analyses of BCG-treated T1HG bladder cancer using Philips OncoSignal: A pilot study

Author

De Jong, Florus C., primary, Laajala, Teemu D., additional, Hoedemaeker, Robert F., additional, Rinaldetti, Sébastien, additional, Mensink, Jolien T., additional, Van Der Made, Angelique C., additional, Van der Schoot, Deric K., additional, Boevé, Egbert R., additional, Zwarthoff, Ellen C., additional, Boormans, Joost L., additional, Theodorescu, Dan, additional, Costello, James C., additional, and Zuiverloon, Tahlita C., additional

Published
2021
Full Text
View/download PDF

16. Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Author

Tu, Megan M., Ng, Terry L., De Jong, Florus C., Zuiverloon, Tahlita C.M., Fazzari, Francesco G.T., and Theodorescu, Dan

Subjects
PD-L1, atezolizumab, nivolumab, durvalumab, Bladder cancer, PD-1, biomarkers, Systematic Review, immunotherapy, avelumab, pembrolizumab
Abstract

Background: The activity of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer (BC) is promising for many patients. However, a subset of patients do not benefit from treatment, thus leading to an effort to better identify predictive molecular biomarkers of response. Objective: To conduct a systematic review of the literature on predictive molecular biomarkers associated with response to PD-1 and PD-L1 inhibitors in advanced bladder cancer, defined as locally-advanced, unresectable, or metastatic (mBC) disease. Methods: A search of the literature was performed using Embase (1947 – January 2019), Medline (1946 – January 2019), and EBM Reviews for Cochrane Central Register of Controlled Trials (as of December 2018). Studies examining the association of molecular biomarkers with clinical outcome in BC treated with PD-1 or PD-L1 monotherapy were included. Outcomes of interest were overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), duration of response, and objective response rate (ORR). Results: Using the study search criteria, 899 unique abstract citations were found, of which 834 did not meet the eligibility criteria. Full text of the remaining 65 citations were screened, and 50 studies excluded, including 18 review articles. Eight additional studies from the bibliography of the review papers were included, making a total of 23 studies. Five PD-1 / PD-L1 antibodies have been tested in BC immunohistochemistry (IHC). These studies used different expression scoring criteria and generally had poor ability to discriminate likelihood for response. Overall, the data suggests CD8+ T cell infiltration is necessary to mediate an antitumor immune response, but other immune cell populations, such as neutrophils may suppress T cell-mediated immunity and efficacy of PD-1/PD-L1 blockade. An IFNγ signature is a promising predictor, but there needs to be consensus on the optimal gene panel composition, and prospective validation. Tumor mutation burden (TMB) is a promising predictor in six studies reporting on 1200 patients, but there is not a consensus on the optimal definition of “high TMB”. Detection of T cell receptor (TCR) clonal expansion has only been conducted in small studies and so its predictive value remains inconclusive. Epithelial-mesenchymal transformation (EMT) and transforming growth factor β (TGFβ) are associated with poor prognosis and possibly intrinsic resistance to PD-1/PD-L1 checkpoint blockade, but more work needs to be done to build upon and confirm the initial findings. Conclusions: Currently no molecular biomarker is sufficiently mature for routine clinical use, while some candidates, or a combination show great promise and need further study.

Published
2019

18. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis

Author

de Jong, Florus C., primary, Hoedemaeker, Robert F., additional, Kvikstad, Vebjørn, additional, Mensink, Jolien T. M., additional, de Jong, Joep J., additional, Boevé, Egbert R., additional, van der Schoot, Deric K. E., additional, Zwarthoff, Ellen C., additional, Boormans, Joost L., additional, and Zuiverloon, Tahlita C. M., additional

Published
2021
Full Text
View/download PDF

22. Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.

Author

Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, and Zuiverloon TCM

Abstract

The global incidence of bladder cancer is more than half a million diagnoses each year. Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC), which accounts for ~75% of diagnoses, and muscle-invasive bladder cancer (MIBC). Up to 45% of patients with NMIBC develop disease progression to MIBC, which is associated with a poor outcome, highlighting a clinical need to identify these patients. Current risk stratification has a prognostic value, but relies solely on clinicopathological parameters that might not fully capture the complexity of disease progression. Molecular research has led to identification of multiple crucial players involved in NMIBC progression. Identified biomarkers of progression are related to cell cycle, MAPK pathways, apoptosis, tumour microenvironment, chromatin stability and DNA-damage response. However, none of these biomarkers has been prospectively validated. Reported gene signatures of progression do not improve NMIBC risk stratification. Molecular subtypes of NMIBC have improved our understanding of NMIBC progression, but these subtypes are currently unsuitable for clinical implementation owing to a lack of prospective validation, limited predictive value as a result of intratumour subtype heterogeneity, technical challenges, costs and turnaround time. Future steps include the development of consensus molecular NMIBC subtypes that might improve conventional clinicopathological risk stratification. Prospective implementation studies of biomarkers and the design of biomarker-guided clinical trials are required for the integration of molecular biomarkers into clinical practice., (© 2024. Springer Nature Limited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results